Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials

被引:36
|
作者
Napoles, A. [1 ]
Cook, E. [2 ]
Ginossar, T. [3 ]
Knight, K. D. [4 ]
Ford, M. E. [5 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ New Mexico, Albuquerque, NM 87131 USA
[4] Med Univ South Carolina, Charleston, SC USA
[5] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
来源
CANCER DISPARITIES | 2017年 / 133卷
关键词
AFRICAN-AMERICAN COMMUNITIES; ETHNIC-MINORITIES; PREVENTION TRIAL; RECRUITMENT; PERCEPTIONS; AWARENESS; WOMEN; INTERVENTION; RETENTION; BARRIERS;
D O I
10.1016/bs.acr.2016.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The underrepresentation of ethnically diverse populations in cancer clinical trials results in the inequitable distribution of the risks and benefits of this research. Using a case study approach, we apply a conceptual framework of factors associated with the participation of diverse population groups in cancer clinical trials developed by Dr. Jean Ford and colleagues to increase understanding of the specific strategies, and barriers and promoters addressed by these strategies, that resulted in marked success in accrual of racially and ethnically diverse populations in cancer clinical research. Results indicate that the studies presented were able to successfully engage minority participants due to the creation and implementation of multilevel, multifaceted strategies that included: culturally and linguistically appropriate outreach, education, and research studies that were accessible in local communities; infrastructure to support engagement of key stakeholders, clinicians, and organizations serving minority communities; testimonials by ethnically diverse cancer survivors; availability of medical interpretation services; and providing infrastructure that facilitated the engagement in clinical research of clinicians who care for minority patient populations. These strategic efforts were effective in addressing limited awareness of trials, lack of opportunities to participate, and acceptance of engagement in cancer clinical trials. Careful attention to the context and population characteristics in which cancer clinical trials are conducted will be necessary to address disparities in research participation and cancer outcomes. These studies illustrate that progress on minority accrual into clinical research requires intentional efforts to overcome barriers at all three stages of the accrual process: awareness, opportunity, and acceptance of participation.
引用
收藏
页码:77 / 94
页数:18
相关论文
共 50 条
  • [31] The Clinical Trials Gap for Adolescents and Young Adults with Cancer: Recent Progress and Conceptual Framework for Continued Research
    Freyer D.R.
    Seibel N.L.
    Current Pediatrics Reports, 2015, 3 (2) : 137 - 145
  • [32] US cancer groups call for more diverse populations to be included in trials
    McCarthy, Michael
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 358
  • [33] The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations
    Hahn, Elizabeth A.
    Beaumont, Jennifer L.
    Pilkonis, Paul A.
    Garcia, Sofia F.
    Magasi, Susan
    DeWalt, Darren A.
    Cella, David
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2016, 73 : 135 - 141
  • [34] Psychosocial Determinants of Socioeconomic Inequalities in Cancer Screening Participation: A Conceptual Framework
    von Wagner, C.
    Good, A.
    Whitaker, K. L.
    Wardle, J.
    EPIDEMIOLOGIC REVIEWS, 2011, 33 (01) : 135 - 147
  • [35] Improving participation of culturally and linguistically diverse participants in clinical trials: an expert consultation
    Watson, Eliza
    Gulline, Hannah
    Jane, Stephen M.
    Woollett, Anne
    Ayton, Darshini
    TRIALS, 2025, 26 (01)
  • [36] The patient experience: Clinical trial knowledge, attitudes and participation among diverse populations
    Strom, Carla
    Winkfield, Karen M.
    Tooze, Janet A.
    Ruiz, Jimmy
    Shore, Kelsey
    Weaver, Kathryn E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [37] A Conceptual Framework for Logistics Management and Project Planning in the Clinical Trials Industry
    Sadoon, Emad
    Venkatadri, Uday
    Ghasemi, Alireza
    LOGISTICS-BASEL, 2023, 7 (04):
  • [38] Applying the estimand framework to clinical pharmacology trials with a case study in bioequivalence
    Lynggaard, Helle
    Mckendrick, Sue
    Baird, Mark
    Kerwash, Essam
    Lanius, Vivian
    Lasch, Florian
    Wright, David
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [39] Patterns of participation of patients in cancer clinical trials (CCTs)
    Morris, Patrick G.
    Kelly, Ronan
    Horgan, Anne
    Nasim, Saira
    Kehily, Derval
    Mc Morrow, Rose
    Collier, Cathal
    Grogan, Liam
    Breathnach, Oscar S.
    ANNALS OF ONCOLOGY, 2006, 17 : 191 - 191
  • [40] Patterns of participation of patients in cancer clinical trials in Ireland
    Morris, P. G.
    Kelly, R.
    Horgan, A.
    Nasim, S.
    Kehily, D.
    Grogan, L.
    Breathnach, O. S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2007, 176 (03) : 153 - 156